Stoke Therapeutics Highlights Strategic Priorities and Anticipated Milestones for 2024
January 8, 2024
– Data anticipated in Q1 2024 from studies of STK-001 for the treatment of Dravet syndrome – – End of Phase 1/2a study result ...Stoke Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
January 4, 2024
BEDFORD, Mass. --(BUSINESS WIRE)--Jan. 4, 2024-- Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated t ...